<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217631</url>
  </required_header>
  <id_info>
    <org_study_id>1262.2</org_study_id>
    <nct_id>NCT02217631</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Trial With Open-label Active Comparator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objectives of the trial were to assess safety, tolerability, pharmacokinetics, and
      pharmacodynamics of multiple rising doses of BI 653048 BS H3PO4 compared with prednisolone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in vital signs</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
    <description>blood pressure, pulse rate, body temperature, orthostatic test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in ECG</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by the investigator on a four-point scale</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma at different time points (Cmax)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from dosing to maximum measured concentration of the analyte at different time points (tmax)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in the plasma over time interval from 0 to the last measurable time point of the dose at different time points (AUC0-tz)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity at different time points (AUC0-∞)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the AUC0-∞ that is obtained by extrapolation at different time points (%AUCtz-∞)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination rate constant at different time points (λz)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after oral administration at different time points (MRTpo)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination half life at different time points (t1/2)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in plasma following extravascular administration at steady state (CL/Fss)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state (Vz/Fss)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration at steady state (Cmin,ss)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Cmax at steady state (Cmax/Dss)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalised AUC0-∞ at steady state (AUC0-∞/Dss)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index of the analyte when comparing AUCτ (RA,AUCτ)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index of the analyte when comparing Cmax (RA,Cmax)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity index (LI)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of analyte excreted in urine unchanged from t1 to t2 interval at different time points (Aet1-t2)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of the unchanged analyte at different time points (CLr)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum biomarker concentration-time curve after the Nth dose (AUECN)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the baseline (before dose level) but above serum biomarker concentration-time curve after the Nth dose (AUECbelow_base)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured serum concentration of the biomarkers after the Nth dose (Emin,N)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured serum concentration of the biomarkers after the Nth dose (Emax,N)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biomarker concentration after the (N-1)th dose but before the Nth dose (Epre,N)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured value of the biomarkers in biological matrix at the set time point after Nth dose (EN)</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose insulin sensitivity (OGIS) index</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment (HOMA) value</measure>
    <time_frame>up to day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 653048 BS H3PO4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 653048 BS H3PO4</intervention_name>
    <arm_group_label>BI 653048 BS H3PO4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone low dose</intervention_name>
    <arm_group_label>Prednisolone low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone high dose</intervention_name>
    <arm_group_label>Prednisolone high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects based on a complete medical history, physical examination, vital
             signs (blood pressure and pulse rate), 12-lead ECG, and clinical laboratory tests

          -  Age of 18 to 50 years

          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             and the local legislation

        Exclusion Criteria:

          -  Any clinically relevant deviation from normal in the medical examination including
             blood pressure, pulse rate, and ECG

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy), psychiatric disorders, or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt;24 h) within at least 1 month or less than 10
             half-lives of the respective drug before first treatment with study drug or during
             trial

          -  Use of drugs which might reasonably influence the results of the trial or which
             prolong the QT/QTc interval within 10 days before first treatment with study drug or
             during trial

          -  Participation in another trial with an investigational drug within 30 days before
             first treatment with study drug or during trial

          -  Smoker (more than 10 cigarettes, 3 cigars, or 3 pipes per day)

          -  Inability to refrain from smoking beginning from 1 day before first treatment with
             study drug until discharge from the clinical unit

          -  Alcohol abuse (more than 60 grams per day)

          -  Drug abuse

          -  Blood donation of more than 100 mL within 4 weeks before first treatment with study
             drug or during trial

          -  Excessive physical activities within 1 week before first treatment with study drug or
             during trial

          -  Any laboratory value outside the reference range and of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of the QT/QTc interval (e.g. QTc intervals that are
             repeatedly longer than 450 ms)

          -  A history of additional risk factors for torsades de points (e.g. heart failure,
             hypokalaemia, or family history of Long QT syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>August 14, 2014</last_update_submitted>
  <last_update_submitted_qc>August 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

